You searched on: Topic Area: Drugs/Pharmaceuticals Sorted by: title
Displaying records 31 to 33.
Resort by: Date / Title
31. Study of interaction of the cyclin-dependent kinase 5 with its activator, p25 and with the p25-derived inhibitor, CIP
NIST Interagency/Internal Report (NISTIR)
Antonio Cardone, Ram D Sriram, Wayne Albers, Harish C. Pant
A high-affinity inhibitor protein called CIP, which can be produced by small truncations of p35, was earlier identified by Amin, Albers, and Pant. P35 is one of the physiological activators of cdk5, a member of the cyclin-dependent kinase family. The ...
32. Testing for the Antiphospholipid Syndrome: Importance of IgA Anti-beta 2-glycoprotein I
T.P. Greco, Michael D. Amos, A.M. Conti-Kelly, J.D. Naranjo, J.W. Ijdo
33. Tumor Necrosis Factor Interaction with Gold Nanoparticles
De-Hao D. Tsai, Sherrie R. Elzey, Frank W DelRio, Robert I. MacCuspie, Suvajyoti S. Guha, Michael Russel Zachariah, Athena M Keene, Jeffrey D Clogston, Vincent A Hackley
We report on a systematic investigation of molecular conjugation of tumor necrosis factor protein-α (TNF) onto gold nanoparticles (AuNPs) and the subsequent binding behavior to its antibody (anti-TNF). We employ a combination of physical and spe ...